Formulation development of diltiazem hydrochloride transdermal drug delivery system utilizing pseudolatex base

Abstract

The formulation and an evaluation of diltiazem hydrochloride (DTZ HCl) with a view to developing and preparing an DTZ HCl releasing system for transdermal applications. Eudragit RL100 and Eudragit RS100 were used to prepare pseudolatex as a drug reservoir patch. These preparations were evaluated for in vitro release across porous membrane, and permeation of the drug across shed snake skin. The release rate of DTZ HCl pseudolatex can be varied by changing the polymer ratio, PVP K30, surfactant, platsticizer, and drug concentrations, respectively. However, In vitro drug release model of all pseudolatex formula appeared to be Higuchi's model while as in vitro drug release mechanism revealed that non fickian diffusion would be operated. The suitable pseudolatex formula, which used to prepare as drug reservoir in patch, composed of DTZ HCl 10%, Eudragit RL100 12%, PVP K30 4%, Tween 80 10%, and dibutyl phthalate 4% w/w of formulation. Then DTZ HCl patch exhibiting skin permeation rate as 6.5 mcg/cm[superscript2]hr[superscript-1/2 followed by Higuchi's model. Preliminary studies on DTZ HCl pseudolatex are indicative of its potentiality for transdermal preparation and establish the further need for in vivo evaluation